Member Info for Brighty1

HE1 could be a 100% riser tomorrow judging by the volume and interest today.

Good luck, Brighty

Exactly right. The BOD are clearly ramping up their plans. This is a 2-3 year investment for me.

In summary:

* The RNS today was excellent news and the agreement signed last week with the Tier1 global leader in vehicle components was very encouraging indeed - especially the news that it includes funding to DGI.

* Prototypes are already being produced and will be ready in H1 2024 and will be followed by vehicle trials in H2 2024.

Good luck, Brighty

A £1 Billion offer would be 30p a share (approx). Not impossible to see this happening.

Good luck, Brighty

Time to buy more HE1 shares today.

Good luck, Brighty

Exactly. We are fast approaching the "value inflection point" for HEMO that Prevail's CEO, Mary Schaheen, has mentioned. i.e. Prevail know the true value attached to being a clinical company, which is a MCAP many multiples of our current share price....

Good luck, Brighty

Yes, I've topped up too with a further 4,542,873 with some of my HE1 gains today. DGi looks the real deal for a 2-3 year investment. 18p from here is a x100. Very possible with the tech they have....Good luck, Brighty

Top takeover targets to watch. Boil get a mention in this review of hot stoks for 2024 by Investing Strategy. See below:

"Baron Oil — farm-up signed, funding possibly imminent, and when the majors finally get in gear and make some decisions, Chuditch will be bought at a significant premium. I am absolutely convinced of this and will continue to add at low prices through 2024. Selling/trading? Don’t complain when the rocket launches".

https://investingstrategy.co.uk/stock-tips/the-buyout-targets-of-2024/

Good luck, Brighty

Like many invested in HEMO I'm very optimstic for a 5p+ share price in advance of (hopefully) the FDA granting HEMO approval.

Encouraging news from the FDA is very likely to catapult our share price to all time highs.

I would recommend a look at AVCT's share price trajectory and Mcap as it's is an interesting model to follow for HEMO investors. They went from 16p to 232p and are still up over 6 times from the 16p days as they progress through clinical trials. Their current Mcap is £310 Million. Ours is £43 Million.

The upside here once we hear about IND/FDA/CAR T, CBR etc and become a clinical company is clearly considerable.

In summary, we could be about to see an all time high share price and Mcap for HEMO within weeks ....

Good luck and have a great weekend, Brighty

MorningtonOz's £1 a share is not as far fetched as it sounds. See the takeover deals in our sector recently below:

* GSK last month paid $1.4 Billion for Aiolos Bio.

* Amgen purchased Horizon Therapeutics for $27.8 Billion

* Pfizer acquired Global Blood Therapeutics for $5.4Billion

* Pfizer bought Biohaven Pharmaceutical for $11.6 Billion in Cash

* Affinivax was bought by GSK for $ 2.10Billion

* AstraZeneca acquired CinCor Pharma for $1.8 Billion

* Thermo Fisher acquired PeproTech for $1.85 Billion

* Pfizer bought Arena for £6.7 Billion

* AZ paid 1 billion for KYM Bio and $2 Billion to partner Quell Therapeutics

* Eli Lilly acquired Versanis for $1.925 billion

* Astellas bought Iveric Bio for $5.9billion

* GSK paid £1.6Billion to buy Bellus

You can see where MorningtonOz is coming from if a takeover of HEMO happened in the next couple of years. A similar kind of £1 Billion deal would see the HEMO share price over £1.

In the short term a significant bounce is very likely on FDA approval before we head much higher with a licencing deal and then a takeover....

Good luck, Brighty

I love your £1 prediction MorningtonOz. Probably 25p a share is more likely in the medium term, which is only a £300 million mcap for HEMO. For example, AVCT gained a MCAP of £300 Million once they became a clinical company. However, I do agree on £1 a share on a billion takeover though. This is very much the norm in our sector these days with big pharma snapping up smaller innovative companies in our space for billions. Check out the JP Morgan qtrly data on deals in the pharma sector to get a feel for just how big the transactions have been over the last few years. Many have been in the billions of pounds for relatively small bios. i.e. this would equate to your £1 a share price......

Good luck, Brighty

The news today that the Farm-Up with TIMOR GAP has become Unconditional is another building block on BOIL's journey to a takeover. It would be good to see an Upland style x15 rise here soon as the momentum builds....

Good luck, Brighty

Exactly, don't rule out 30p by the end of the year. I've been saying it for quite a while here. 2 of my shares in the last 6 months have gone up over x 10. UPL 0.5 to 8p and POS 2p - 30p. A £300 Million Mcap in our sector is peanuts. I think the initial x 3 rise on positive FDA news looks about right judging by other gains in our space. Hopefully not too long to wait now...

Good luck, Brighty

Excellent results today. EBITDA increased by 180% against the prior period to £1.4m.

13p a share currently undervalues MTEC significantly. A re-rate is on the cards here. MTEC's share price was over x 10 at 140p not so long ago and just 12 months ago was over 40p a share.

* MTEC also saw revenue for the period of £19.1m.

* MTEC is debt free and has a strong balance sheet with £7.9m net cash at the Period end.

* During the Period MTEC won £12.6m in new contracts.

Good luck, Brighty

Exactly Stay Long. Real progress is being made by DGI now.

* The agreement signed with the Tier1 global leader in vehicle components was very encouraging indeed - especially the news that it includes funding to DGI.

* This is mission critical to an R&D based company, avoiding fund raising.

* The fact that Prototypes are already being produced and will be ready in H1 2024 and will be followed by vehicle trials in H2 2024 is the tipping point for DGI.

* Most commercially exciting of all is that this is being funded or part funded by the Tier1 global leader.

* DGI has to be one of the most attractive innovative small caps to be invested in alongside the likes of GST, HE1 and HEMO currently. For me DGI has the biggest upside over the next 3 years....

Good luck, Brighty

AVCT gained a MCAP of £300 Million once they became a clinical business. That equates to 25p a share for HEMO. We are on the launchpad.....

Good luck, Brighty

Yes, 33p would be fantastic and with Prevail InfoWorks acting as the CRO for the upcoming Phase I clinical trial we are fast approaching the "value inflection point" for HEMO that Prevail's CEO, Mary Schaheen, has mentioned. i.e. Prevail know the true value attached to being a clinical company, which is a MCAP many multiples of our current share price. e.g. The average licencing deal in our sector last year was $47 Million dollars.…..

Good luck, Brighty

As you say 2p next stop but probably 3p+ within days. Don't forget that 4p a share was achieved in the last quarter. A contract win or two could see that repeated or positive court case news......

Good luck, Brighty

Yes, main market, I know. My 7am fog! Excellent long term investment. I'm here for the long haul....

Good luck, Brighty

Yes, DGI look to be the real deal on AIM. Probably one of the best long term holds I've seen in a long time. There might be something to the HE1 news though....

Good luck, Brighty

Excellent update from DGI today:

* Agreement signed with a global leader in commercial vehicle components

* Partner is a Tier one commercial vehicle components company

* Agreement is to jointly develop systems for heavy goods vehicles applications utilising DG Innovate's Pareta drive technology

AND...

* The Agreement includes funding to the Company, covering the first proof of concept stage, that will see prototypes produced in H1 2024, followed by on vehicle trials in H2 2024.

Real progress being made by DGI ....

Good luck, Brighty